AbCellera Biologics Long Term Debt

AbCellera Biologics's long-term debt stands at $130M as of March 2026. That compares with $63M in the prior-year period — up 112.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

AbCellera Biologics reported $130M in long-term debt versus $63M a year earlier — a 112.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $63M in the prior-year period — up 112.5% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how AbCellera Biologics's long-term debt evolved across reporting periods, while the comparison chart places ABCL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.